Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of GC3114 in Elderly Healthy Subjects
NCT03657719Phase 2Completed
- Sponsor
- GC Biopharma
- Start
- Oct 2018
- Primary completion
- Dec 2018
- Modality
- Recombinant Proteins and Enzymes, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of High-dose quadrivalent influenza vaccine in influenza (2 arms), sponsored by GC Biopharma. Primary endpoint: Adverse Event at 7 days. Started Oct 2018; status: completed.
02
Drugs
High-dose quadrivalent influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03657719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03657719.